- Published at
- by thestockmarketwatch.com
mixed
mixed
News for Vaxart, Inc. (VXRT)
- Published at
- by markets.businessinsider.com
positivepositiveVaxart CEO Issues Letter to Stockholders Highlighting Company Progress
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms ...- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralVaxart to Present at the Citizens Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that members of the management team will present at the C- Published at
- by gurufocus.com
positivepositiveVaxart (VXRT) Completes Enrollment for Phase 1 Norovirus Vaccine Trial | VXRT Stock News
Vaxart (VXRT) has successfully finished enrolling participants for its Phase 1 clinical trial, which is assessing the effectiveness of its new oral norovirus va- Published at
- by gurufocus.com
neutralneutralVaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that it complete- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralVaxartto Present at World Vaccine Congress Washington 2025 on April 23
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Office- Published at
- by manilatimes.net
positivepositive- Published at
- by insidermonkey.com
positivepositiveVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference call.- Published at
- by gurufocus.com
neutralneutralVaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations
Cash Position: Cash, cash equivalents, and investments totaled $51.7 million as of December 31, 2024, providing financial runway through multiple development m- Published at
- by gurufocus.com
positivepositiveQ4 2024 Vaxart Inc Earnings Call Transcript
Mar 20, 2025 / 08:30PM GMTOperator Greetings and welcome to the Vaxart Business update in fourth quarter and full year 2024 financial results conference call. A- Published at
- by seekingalpha.com
positivepositiveVaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ETCompany ParticipantsEd Berg - SVP and General CounselSteven Lo -...- Published at
- by zacks.com
negativenegativeVAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralVaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced it will provide- Published at
- by gurufocus.com
neutralneutralVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced the initi- Published at
- by manilatimes.net
neutralneutral- Published at
- by zerohedge.com
positivepositiveRFK Jr Pauses Multi-Million Dollar Contract To Develop New COVID-19 Vaccine
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero- Published at
- by manilatimes.net
mixedmixed